NasdaqGS:SRPTBiotechs
Sarepta Broadens Beyond Elevidys With siRNA Progress And FDA Milestones
Sarepta Therapeutics (NasdaqGS:SRPT) is progressing its small interfering RNA (siRNA) candidates SRP-1001 and SRP-1003, with early data viewed as encouraging.
The company is seeking to transition AMONDYS 45 and VYONDYS from accelerated to traditional FDA approvals through recent regulatory submissions.
These updates come as Sarepta refines its commercial focus beyond gene therapy Elevidys, which continues to face regulatory and commercial complexity.
Sarepta Therapeutics focuses on rare...